NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients
A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients
CompletedPhase 4
Sponsor: University of Liverpool
Conditions: Type 2 Diabetes Mellitus
Interventions: Dapagliflozin, Standard of Care
Countries: United Kingdom
A trial of patients with type 2 diabetes mellitus to evaluate the comparative effectiveness between dapagliflozin and Standard of Care (SOC)
Eligibility overview
Sex: ALL
Age: 18 Years to 75 Years
Healthy volunteers: No
Study type: INTERVENTIONAL
Eligibility criteria
Inclusion Criteria: For inclusion in the study patients should fulfil the following criteria at the time of screening: 1. Provision of informed consent prior to any study specific procedures 2. Females and males aged ≥18 years up to ≤ 75 years 3. Diagnosed with Type 2 Diabetes Mellitus. 4. Uncontrolled on first-line metformin treatment, defined as ≥8 weeks on maximum tolerated dose of metformin and HbA1c \> 6.5%. 5. Ability to read and write as judged by the investigator. Exclusion Criteria: Patients should not enter the study if any of the following exclusion criteria are fulfilled: 1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site) 2. Previous enrolment or randomization in the present study 3. Age \> 75 years 4. Pregnancy/active breast feeding at the time of inclusion 5. Known moderate to severe renal impairment (eGFR\<60ml/min). 6. Participation in an interventional clinical trial ≤ 3 months before enrolment. 7. Unsuitable to participate on mental health grounds, as judged by the investigator. 8. Physician decision to use, as second line treatment, insulin, a GLP1 agonist compound or a SGLT2 inhibitor different from dapagliflozin. 9. Presence of any of the characteristics in which the products in study are contraindicated, as per current labels.
Locations (132)
- Forfar, Angus, United Kingdom
- Yate, Avon, United Kingdom
- Bracknell, Berkshire, United Kingdom
- Reading, Berkshire, United Kingdom
- Wokingham, Berkshire, United Kingdom
- Birmingham, Birmingham, United Kingdom
- Maesteg, Bridgend, United Kingdom
- Chew Stoke, Bristol, United Kingdom
- Yate, Bristol, United Kingdom
- Iver, Bucks, United Kingdom
- Blackwood, Caerphilly, United Kingdom
- Hengoed, Caerphilly, United Kingdom
- Greenisland, Carrickfergus, United Kingdom
- Whitehead, Carrickfergus, United Kingdom
- Macclesfield, Cheshire, United Kingdom
- Crook, County Durham, United Kingdom
- Denbigh, Denbighshire, United Kingdom
- Exeter, Devon, United Kingdom
- Hull, East Yorkshire, United Kingdom
- Romford, Essex, United Kingdom
- Pinhoe, Exeter, United Kingdom
- Cheltenham, Gloucestershire, United Kingdom
- Trafford, Greater Manchester, United Kingdom
- Worsley, Greater Manchester, United Kingdom
- Alton, Hampshire, United Kingdom
- Farnborough, Hampshire, United Kingdom
- Gosport, Hampshire, United Kingdom
- Havant, Hampshire, United Kingdom
- Romsey, Hampshire, United Kingdom
- Southampton, Hampshire, United Kingdom
- + 102 more on CT.gov